Trial · NCT01661790
Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
NCT01661790, Phase 3, Completed, Chinese PLA General Hospital; results first posted 2015-03-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer. Trials, record NCT01661790. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01661790
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
- NCT number
- NCT01661790
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 72 participants, actual
- Lead sponsor
- Chinese PLA General Hospital
- Conditions
- Malignant Pleural Effusion
- Interventions
- Bevacizumab, Cisplatin
- First posted
- 2012-08-10
- Last updated
- 2015-03-25
- Results first posted
- 2015-03-25
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With "Complete Response" and "Partial Response" | from randomization, This treatment was given every two weeks,responses were made by biweekly | Response assessed by type-B ultrasonic tests; Complete remission (CR) was considered when the accumulated fluid had disappeared and was stable for at least four weeks; partial remission (PR) was considered when \>50% of the accumulated fluid had disappeared, symptoms had improved, and the remaining fluid had failed to increase for at least four weeks; The total efficiency ORR was calculated by taking the sum of CR+PR |
| Secondary | Median Progression Free Survival (PFS) | baseline to biweekly,until disease progression | |
| Secondary | Overall Survival (OS) | randomization to four weeks,until death | |
| Secondary | Adverse Reactions | Up to 1 month after the last treatment | |
| Secondary | Qualify of Life (QoL) | baseline to biweekly,until death | |
| Other | Quantitative RT-PCR(Reverse Transcription-Polymerase Chain Reaction) for VEGF-A(Vascular Endothelial Growth Factor A) | before intrapleural administration |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Complete Response and Partial Response | from randomization, This treatment was given every two weeks,responses were made by biweekly | participants | NUMBER | |
| SECONDARY | Median Progression Free Survival (PFS) | baseline to biweekly,until disease progression | |||
| SECONDARY | Overall Survival (OS) | randomization to four weeks,until death | |||
| SECONDARY | Adverse Reactions | Up to 1 month after the last treatment | |||
| SECONDARY | Qualify of Life (QoL) | baseline to biweekly,until death | |||
| OTHER_PRE_SPECIFIED | Quantitative RT-PCR(Reverse Transcription-Polymerase Chain Reaction) for VEGF-A(Vascular Endothelial Growth Factor A) | before intrapleural administration |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Complete Response and Partial Response | Bevacizumab & Cisplatin | CR | 17 | participants | |
| Number of Participants With Complete Response and Partial Response | Cisplatin | CR | 2 | participants | |
| Number of Participants With Complete Response and Partial Response | Bevacizumab & Cisplatin | PR | 13 | participants | |
| Number of Participants With Complete Response and Partial Response | Cisplatin | PR | 15 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Bevacizumab & Cisplatin | 36 | |
| Overall Study | STARTED | Cisplatin | 36 | |
| Overall Study | COMPLETED | Bevacizumab & Cisplatin | 36 | |
| Overall Study | COMPLETED | Cisplatin | 34 | |
| Overall Study | NOT COMPLETED | Bevacizumab & Cisplatin | 0 | |
| Overall Study | NOT COMPLETED | Cisplatin | 2 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Leucocytopenia | Blood and lymphatic system disorders | Bevacizumab & Cisplatin | 24 | 36 | 24 |
| other | Leucocytopenia | Blood and lymphatic system disorders | Cisplatin | 22 | 36 | 22 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Bevacizumab & Cisplatin | ||
| Total, all-cause mortality | Cisplatin | ||
| Total, other adverse events | Bevacizumab & Cisplatin | 24 | 36 |
| Total, other adverse events | Cisplatin | 22 | 36 |
| Total, serious adverse events | Bevacizumab & Cisplatin | 0 | 36 |
| Total, serious adverse events | Cisplatin | 0 | 36 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Bevacizumab & Cisplatin vs Cisplatin: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01661790
GET https://conductscience.org/api/trials/v1/NCT01661790/registered